Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vicuron Will Resubmit Anidulafungin For Invasive Candidiasis Under Separate NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Current NDA will focus on esophageal candidiasis indication; Vicuron plans to submit an amendment in second quarter 2005 to address FDA’s concerns about the “approvable” antifungal. Invasive candidiasis NDA filing is slated for third quarter 2005.

You may also be interested in...



Pfizer “Approvable” Streak Continues With Second letter For Anidulafungin

The antifungal agent’s second approvable letter is for an esophageal candidiasis indication.

Pfizer “Approvable” Streak Continues With Second letter For Anidulafungin

The antifungal agent’s second approvable letter is for an esophageal candidiasis indication.

Vicuron Submits NDA For Additional Anidulafungin Indication

The invasive candidiasis/candidemia indication was spun off from a pending NDA for esophageal candidiasis.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel